Members of the ProfiLER trial identified actionable mutations in more than half of individuals with advanced cancers, though only a fraction received targeted therapy.
The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering.
An epigenetic analysis showed that the tumors all shared a certain DNA methylation signature, but that methylation patterns varied between samples.
The partners aim to identify master regulators in the molecular networks of GIST patients that can serve as drug targets for existing treatments.
Rare germline mutations in cancer risk genes turned up in more than half of sarcoma patients tested by gene panel sequencing.
The UPenn-led study proposal calls for editing three genes in autologous T cells with CRISPR and includes preliminary data for on- and off-target editing.
An analysis of angiosarcoma-derived cell lines identified a NUP160-SLC43A3 fusion that subsequently turned up in aggressive primary tumor samples.
A five-gene signature was linked to both event-free survival and overall survival in individuals with a type of rhabdomyosarcoma missing a prognostically informative gene fusion.
The group is currently comparing a lab-developed nCounter assay to "gold-standard" RT-PCR assays to retrospectively analyze sarcoma patient samples.
MGH runs the clinical fusion assay for all lung cancer patients and the Snapshot NGS test on all patients with solid tumors. It is planning to expand the assays and is also developing a fusion panel for hematological malignancies.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.
In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.